Expand BBIO Menu
BBIO MENU

BBIO Latest Press Releases

-- March 4, 2026 --

BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference Globe Newswire 7:30 AM

-- February 24, 2026 --

BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates Globe Newswire 4:01 PM

-- February 23, 2026 --

BridgeBio to Participate in March Investor Conferences Globe Newswire 7:30 AM

-- February 17, 2026 --

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 6:22 PM
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET Globe Newswire 7:30 AM

-- February 12, 2026 --

BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia Globe Newswire 7:30 AM

-- January 27, 2026 --

CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 5:10 PM
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- January 16, 2026 --

BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 Globe Newswire 1:00 AM

-- January 14, 2026 --

BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 Globe Newswire 4:01 PM

-- January 12, 2026 --

BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 10:30 AM

-- January 5, 2026 --

BridgeBio to Participate in the J.P. Morgan Healthcare Conference Globe Newswire 7:30 AM

-- January 2, 2026 --

BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET Globe Newswire 7:30 AM

-- November 25, 2025 --

BridgeBio to Participate in December Investor Conferences Globe Newswire 7:30 AM

-- November 19, 2025 --

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- November 8, 2025 --

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations Globe Newswire 10:41 AM

-- November 4, 2025 --

BridgeBio to Participate in November Investor Conferences Globe Newswire 7:30 AM

-- November 3, 2025 --

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025 Globe Newswire 7:30 AM

-- October 29, 2025 --

BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates Globe Newswire 4:01 PM
BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1 Globe Newswire 7:00 AM

-- October 28, 2025 --

BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th Globe Newswire 4:01 PM

-- October 27, 2025 --

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study Globe Newswire 7:00 AM

-- October 24, 2025 --

BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week Globe Newswire 4:01 PM
Market Data Delayed 15 Minutes